Company intelligence / Profile preview

Sight Diagnostics

Tel Aviv-Yafo, Tel Aviv District, Israel

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Sight Diagnostics' OLO platform is FDA 510(k) cleared for complete blood count (CBC) and approved in several global markets. Its clinical performance has been validated for providing lab-grade CBC results from a finger prick or venous blood within minutes. Parasight platform is commercially used for rapid and accurate malaria diagnosis in 25 countries.

Therapeutic areas: OncologyHematologyInfectious DiseasesImmunology
Modalities: DeviceArtificial intelligence
Industry: Pathology

Partnerships

Sheba Medical CenterAmerican Association for Clinical Chemistry (AACC)Oxford University Hospitals NHS Foundation TrustInter Medico (Canada distributor)

Beyond the preview

Go deeper on Sight Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sight Diagnostics.

Explore the full profile